Tilray Inc (NASDAQ:TLRY) shares climbed 15% to US$1.98 in early trading on Thursday after the cannabis company announced that it swung to an adjusted net profit of $3.9 million for its fiscal first quarter 2025, from loss of $6.1 million during the same period last year. Its net revenue for the quarter rose 5% to $209.5 million, boosted by a 12% year over year increase in Canadian adult-use cannabis sales and 10% growth in international cannabis revenue.

Haleon PLC's (LSE:HLN, NYSE:HLN) management could be forgiven for feeling like pharmacists rearranging the medicine cabinet while the queue outside keeps growing. Barclays, in a detailed preview ahead of the company's third-quarter results, says the consumer health group's biggest headache remains its US inventory build-up, a problem Haleon is determined to “clean up” before year-end.

REGN secures FDA approval to expand Libtayo's label for high-risk skin cancer, boosting its oncology momentum amid Eylea sales pressure.

Amphenol (APH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Beyond analysts' top-and-bottom-line estimates for Wells Fargo (WFC), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2025.

Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Evaluate Costco's (COST) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for JPMorgan Chase & Co. (JPM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.

Get a deeper insight into the potential performance of FB Financial (FBK) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Goldman (GS), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.

Get a deeper insight into the potential performance of Hancock Whitney (HWC) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Domino's Pizza (DPZ), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.

Get a deeper insight into the potential performance of Citigroup (C) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Evaluate the expected performance of Albertsons Companies (ACI) for the quarter ended August 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Evaluate the expected performance of BlackRock (BLK) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Eli Lilly (LLY) stock merits your attention. Why? Because it offers monopoly-like high margins at a reduced price.

D and PCG are Sempra's competitors in the Multi-Utilities sector that possess:

After posting its largest single-day gain of 2025, small-cap chip stock Aehr Test Systems NASDAQ: AEHR just took a huge hit. On Oct. 7, shares closed down by more than 17% as the market reacted to the company's latest earnings report.

Novo Nordisk A/S (NYSE:NVO) is down 1% to trade at $59 this morning, after news surfaced that the pharmaceutical concern has entered an agreement to purchase U.S.-based peer Akero Therapeutics Inc (NASDAQ:AKRO) for as much as $5.2 billion in cash.

AEM's 52% six-month rally, strong cash flows and project progress suggest more upside as gold prices hit historic highs.